More January U.S. price hikes take 2020 tally to over 330 drugs with higher cost
AbbVie Inc on Thursday raised the cost of rheumatoid arthritis treatment Humira, the world's top-selling medicine, joining other drugmakers that have now hiked U.S. prices of more than 330 prescription drugs for 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Adalimumab in Pediatric Patients With Severe Plaque Psoriasis Adalimumab in Pediatric Patients With Severe Plaque Psoriasis
This analysis reports results from the first RCT comparing the efficacy and safety of the biologic adalimumab with methotrexate for severe plaque psoriasis in children.The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 27, 2019 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

EMA Panel Backs Adalimumab Biosimilar Amsparity EMA Panel Backs Adalimumab Biosimilar Amsparity
The CHMP has recommended approval of Pfizer's adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 16, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Biosimilar for Crohn's Noninferior to Adalimumab Biosimilar for Crohn's Noninferior to Adalimumab
A patent dispute means that the marketing of a biosimilar for patients with inflammatory bowel disease will be delayed, despite approval by the US Food and Drug Administration, investigators report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Abrilada (Adalimumab-afzb Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 2, 2019 Category: Drugs & Pharmacology Source Type: news

Abrilada (Adalimumab-afzb Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 26, 2019 Category: Drugs & Pharmacology Source Type: news

Pfizer nabs FDA approval for Humira biosim
Abrilada is the fifth Humira biosimilar approved in the U.S. and will join generics from Mylan, Samsung Bioepis and Sandoz when AbbVie's blockbuster has its patent expire in 2023. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 19, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2019 Category: Drugs & Pharmacology Source Type: news

Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA ’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
FDA has taken another step to further foster biologics competition with the approval of 25th biosimilar, Abrilada (adalimumab - afzb), a biosimilar to Humira. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 16, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2019 Category: Pharmaceuticals Source Type: news

China's Bio-Thera Gets Approval for Humira Biosimilar China's Bio-Thera Gets Approval for Humira Biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira (adalimumab), paving the way for the first such biosimilar to enter the world's second-largest drug market.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 9, 2019 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

China's Bio-Thera gets approval for Humira biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market. (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx (secukinumab) can beat the world's best-selling drug Humira (adalimumab) in treating a type of arthritis.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 5, 2019 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novartis arthritis drug " narrowly misses " against Humira
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug, Cosentyx, can beat the world's best-selling drug Humira in treating arthritis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 1, 2019 Category: Pharmaceuticals Source Type: news

Risk for Birth Defects Not Increased With Adalimumab
FRIDAY, Nov. 1, 2019 -- Adalimumab exposure in pregnancy does not increase the risk for birth defects, according to a study published online Oct. 18 in PLOS ONE. Christina D. Chambers, from the University of California San Diego in La Jolla, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news

Novartis arthritis drug falls short in challenge to global bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Therapeutic IBD Drug Concentrations May Vary With Different Assays Therapeutic IBD Drug Concentrations May Vary With Different Assays
In patients with inflammatory bowel disease (IBD), concentrations of infliximab and adalimumab varied depending on whether they were assessed with the Enzyme-Linked Immunosorbent Assay (ELISA) or the Homogeneous Mobility Shift Assay (HMSA), researchers found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Study Suggests Adalimumab Exposure in Pregnancy Does Not Increase...
602 Pregnancies Examined by the Non-Profit Organization of Teratology Information Specialists(PRWeb October 18, 2019)Read the full story at https://www.prweb.com/releases/study_suggests_adalimumab_exposure_in_pregnancy_does_not_increase_birth_defects_risk/prweb16660500.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 18, 2019 Category: Pharmaceuticals Source Type: news

Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 10, 2019 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news

Humira, Rituxan top list of U.S. drugs with biggest price increases: report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2019 Category: Drugs & Pharmacology Source Type: news

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news

Adalimumab procurement framework extended
NHS England has extended the procurement framework for adalimumab by four months to 31 March 2020. (Source: NHS Networks)
Source: NHS Networks - September 9, 2019 Category: UK Health Source Type: news

NHS saves £300MILLION in a year by telling doctors to stop giving out expensive branded medications
Hospitals spent £290million on adalimumab - a drug primarily used to treat arthritis but also given to patients with Crohn's disease - in 2018/19. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2019 Category: Consumer Health News Source Type: news

These are the top 25 costliest prescription drugs for Oregon insurers
Humira is the best-selling medicine in the world and a gold mine for drug maker AbbVie, bringing in $4.87 billion in revenue globally in the second quarter. The drug, which treats rheumatoid arthritis and Crohn's disease, costs upwards of $60,000 a year. So it may come as no surprise that Humira is on the list of the 25 most costly drugs for Oregon health insurers in 2018. The combined list is based on the rankings submitted by nine insurance comp anies and takes into account total annual spending,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2019 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news

AbbVie ’s Humira follow-up gets FDA nod
A potential new blockbuster from AbbVie has gotten the go-ahead from the FDA. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 19, 2019 Category: Pharmaceuticals Source Type: news

AbbVie prices new rheumatoid arthritis drug at $59,000 a year
AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition. (Source: Reuters: Health)
Source: Reuters: Health - August 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Hadlima (Adalimumab-bwwd Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 1, 2019 Category: Drugs & Pharmacology Source Type: news

Adalimumab in tight-control approach cost effective in Crohn's
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2019 Category: Drugs & Pharmacology Source Type: news

Humira biosim wins FDA approval
The clock is ticking on how much longer the world ’s best-selling drug will be free from biosimilar competition in the U.S. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 24, 2019 Category: Pharmaceuticals Source Type: news

Merck's Biosimilar to AbbVie's Humira Wins FDA Approval Merck's Biosimilar to AbbVie's Humira Wins FDA Approval
The U.S. Food and Drug Administration approved Merck& Co Inc's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira (adalimumab), the health agency said on Tuesday.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 24, 2019 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Samsung Bioepis Humira biosimilar wins FDA approval
(This story corrects to show that Hadlima belongs to Samsung Bioepis not Merck& Co Inc, which is commercializing the drug in the United States) (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Hadlima (adalimumab-bwwd), a Biosimilar to Humira
INCHEON, Korea– July 24, 2019– Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hadlima (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab)i, for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 24, 2019 Category: Drugs & Pharmacology Source Type: news

Merck's biosimilar to AbbVie's Humira wins FDA approval
The U.S. Food and Drug Administration approved Merck& Co Inc's biosimilar to AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, the health agency said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - July 23, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

There Is No Single, Best Policy for Drug Prices
Most Americans would like the government to act, but a one-size-fits-all approach is unlikely to be the answer. (Source: NYT)
Source: NYT - July 15, 2019 Category: American Health Authors: Austin Frakt Tags: Drugs (Pharmaceuticals) Prices (Fares, Fees and Rates) Inventions and Patents Generic Brands and Products Food and Drug Administration Humira (Drug) Source Type: news

adalimumab (Humira)
Title: adalimumab (Humira)Category: MedicationsCreated: 1/22/2003 12:00:00 AMLast Editorial Review: 7/1/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - July 1, 2019 Category: Rheumatology Source Type: news

Proactive Drug Monitoring Improves Outcomes in Kids With Crohn ’ s Proactive Drug Monitoring Improves Outcomes in Kids With Crohn ’ s
Proactive therapeutic-drug monitoring (TDM) in children with Crohn's disease on adalimumab reduces clinical exacerbations compared to reactive TDM, a randomized controlled trial shows.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

AbbVie to buy Botox maker Allergan for $63 billion
The acquisition aims to diversify AbbVie beyond its top-selling drug Humira, which will soon lose patent protection (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 25, 2019 Category: Consumer Health News Source Type: news

AbbVie to Acquire Allergan in Transformative Move for Both Companies
Provides immediate scale and profitability to AbbVie's growth platform, excluding Humira, significantly expanding and diversifying its revenue base with new therapeutic areas, including Allergan's leading medical aesthetics business Enhances long-term R... Biopharmaceuticals, Mergers & Acquisitions AbbVie, Allergan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2019 Category: Pharmaceuticals Source Type: news

Botox Maker Allergan Is Sold to AbbVie in $63 Billion Deal
The transaction would give AbbVie a potent source of popular treatments as it faces the loss of patent protection for its best-selling drug, Humira. (Source: NYT Health)
Source: NYT Health - June 25, 2019 Category: Consumer Health News Authors: Michael J. de la Merced Tags: Allergan Inc Mergers, Acquisitions and Divestitures Drugs (Pharmaceuticals) AbbVie Inc Botox (Drug) Source Type: news

Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
INDIANAPOLIS, June 14, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that the company will present positive findings from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriati... Biopharmaceuticals Eli Lilly, psoriatic arthritis, Taltz, ixekizumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2019 Category: Pharmaceuticals Source Type: news

On The Toxicity Of Humira And Other Rheumatoid Arthritis Drugs
But articles that trumpet 34,000 deaths on important medicines, that denigrate the FDA ’s approval process and that suggest these drugs shouldn’t be on the market, don’t really help the discussion. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 4, 2019 Category: Pharmaceuticals Authors: John LaMattina, Contributor Source Type: news

Long-Term Safety and Efficacy of ABP 501 in Patients With RA Long-Term Safety and Efficacy of ABP 501 in Patients With RA
How does the safety and efficacy of the adalimumab biosimilar ABP 501 compare with that of the reference product?Arthritis Research & Therapy (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 31, 2019 Category: Allergy & Immunology Tags: Rheumatology Journal Article Source Type: news

What ’s the Latest in Drug-Delivery Devices?
To simplify drug delivery for patients and practitioners, drug-delivery devices are becoming more complex. Many of today’s devices include special features designed to ease self-dosing and encourage patient adherence with novel regimens. Wearable devices are further easing use by promoting active lifestyles. And some devices are offering connectivity to support digital health monitoring. With so many possibilities, where do device developers and pharmaceutical companies begin? MD+DI asked Eric Resnick, vice president and chief technology officer, innovation and technology, West Pharmaceutical Services Inc...
Source: MDDI - May 22, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Packaging Source Type: news

Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation
Settlement provides Boehringer Ingelheim with a clear path to secure patient access to Cyltezo® in the U.S. License period places Boehringer Ingelheim's biosimilar among the first to compete with Humira® in the U.S. RIDGEFIELD, Conn., May 14,... Biopharmaceuticals, Litigation, Licensing Boehringer Ingelheim, AbbVie, Cyltezo, adalimumab, biosimilar, Humira (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 14, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Resolves HUMIRA(R) (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim
NORTH CHICAGO, Ill., May 14, 2019 -- (Healthcare Sales & Marketing Network) -- AbbVie (NYSE: ABBV) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant BI a... Biopharmaceuticals, Litigation, Licensing AbbVie, Boehringer Ingelheim, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 14, 2019 Category: Pharmaceuticals Source Type: news

AbbVie raises forecasts despite pressure on Humira
Blockbuster drug’s revenue outside US takes hit from new competition (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 25, 2019 Category: Pharmaceuticals Source Type: news

AbbVie's Skyrizi drug to treat psoriasis wins U.S. approval
AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, Humira, faces patent pressures. (Source: Reuters: Health)
Source: Reuters: Health - April 24, 2019 Category: Consumer Health News Tags: healthNews Source Type: news